Robert Preidt, an Ontario-based writer and photographer with 20 years’ newspaper and magazine experience; whose work has won numerous awards and appeared in the Toronto Star, the Medical Post and Family Practice magazine, recently released an article on HealthDay.com featuring a new type of blood test able to track the severity and spread of advanced melanoma at an earlier stage, making it significantly more effective than the current tests.
For expats living in the Yucatan Peninsula, skin cancer and melanoma are always a concern, due to high exposure to the sun rays people down here experience on a daily basis.
A new blood test might improve doctors’ ability to track the spread of advanced melanoma skin cancer, according to results of a small, preliminary study.
The test monitors blood levels of DNA fragments from dead cancer cells, and is more effective than the current test at tracking the severity and spread of advanced melanoma, the researchers said.
“Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma,” study senior investigator Dr. David Polsky, from NYU Langone Medical Center in New York City, said in a center news release.
Currently, a test that measures blood levels of an enzyme called lactate dehydrogenase (LDH) is done to guide management of the cancer. LDH levels rise during aggressive tumor growth. However, levels of LDH also rise due to other diseases and biological functions, the study authors pointed out.
The new test assesses levels of circulating tumor DNA (ctDNA) released into the blood when tumor cells die, the researchers said.
The study included 31 patients with inoperable advanced (metastatic) melanoma who had both tests done.
The study found that blood levels of ctDNA were elevated in 80 percent of patients about to undergo treatment for the advanced melanoma. Blood levels of LDH were elevated in just 30 percent of such patients, the study showed.
Also, the ctDNA blood test detected cancer recurrence — confirmed by X-ray or CT scan — in 85 percent of patients tested and undergoing treatment. The LDH blood test detected 54 percent of such cases, the researchers said.
“Previous studies have suggested that ctDNA blood testing may also help monitor progression of breast and colon cancers”, Polsky, a dermatologist, said in the news release.
The new study findings are published in the January issue of the journal Molecular Oncology.
The U.S. National Cancer Institute has more about melanoma.
SOURCE: NYU Langone Medical Center, news release, Jan. 11, 2016
more recommended stories
AMLO continues to criticize US investigation
MEXICO CITY (AP) — On Monday,.
AMLO says U.S. gets Mexico stance on ex-defense chief
MEXICO CITY (Reuters) – Mexico’s president.
Public apology to Yucatecan journalist sets historic precedent
In an event that marks a.
I will continue to use Facebook as long as they do not censor me: AMLO
President Andrés Manuel López Obrador assured.
The US says there is uncertainty about Mexico’s regulatory process, especially in the energy sector
The administration of Donald Trump warned.
Covid rebound in Mérida and the rest of Yucatan
This Sunday, January 17, there was.
Mexico accepts reduction of Pfizer vaccines and to allocate them to poor countries: AMLO
President López Obrador reported that his.
Doctor in charge of Covid-19 vaccination campaign in Mexico resigns
El Universal (January 18, 2021).- Dr. Miriam.
Biden administration to migrant caravan: Don’t come, you won’t get in immediately
WASHINGTON — As thousands of Honduran.
One of the Twin Houses of Paseo Montejo opens to the public as a museum
The place preserves 1911 intact the.